Medical Condition News

RSS

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

Results from a study conducted by Majestic Research suggest that Bristol Myers Squibb's Orencia, Johnson & Johnson's Remicade, and Amgen's/Wyeth's Enbrel will forfeit share of the rheumatoid arthritis market to Roche's newly launched Actemra. Early switching data from Majestic’s proprietary panel of rheumatologists indicates that Orencia may be the biggest loser of all, as 54% of switches to Actemra thus far have been from Orencia.

9 Mar 2010

New program specifically tailored to teens could help them manage and avoid asthma

An asthma program specifically tailored to teens could help those in rural areas manage their disease and avoid potentially fatal complications, Medical College of Georgia researchers say.

9 Mar 2010

RDS launches international outreach program on cognitive impairment in Down syndrome patients

Research Down Syndrome has launched an international outreach program to focus awareness and support for the rapidly advancing area of biomedical research leading to safe and effective approved medical therapies to treat cognitive impairment in individuals of all ages with Down syndrome -- improving memory, learning and communication.

9 Mar 2010

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

ISTA Pharmaceuticals, Inc., today announced the Company's supplemental New Drug Application (sNDA) for once-daily XiDay™ (bromfenac ophthalmic solution) has been accepted for review by the U.S. Food and Drug Administration (FDA).

8 Mar 2010

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.

8 Mar 2010

FDA approves Taro Pharmaceutical Industries' Fluorouracil Topical Cream ANDA

Taro Pharmaceutical Industries Ltd. today reported that it received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Fluorouracil Topical Cream USP, 5%.

8 Mar 2010

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX™ is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture patients with a palpable cord. Dupuytren's contracture is a debilitating disease resulting from excessive collagen deposition that causes contractures of the fingers.

8 Mar 2010

Rcadia Medical Imaging receives CE Mark for COR Analyzer System

Rcadia Medical Imaging today announced that it has received a CE Mark for the COR Analyzer® System, its proprietary software that helps identify patients with significant CAD (Coronary Artery Disease) by a fully automatic analysis of coronary CT angiography (cCTA) studies. The CE Mark allows the company to market the system in the European Union and other countries that accept the CE Mark registration. The COR Analyzer is marketed in the U.S. under 510(k) clearance and Rcadia was named 2009 Best New Radiology Vendor by AuntMinnie.com.

8 Mar 2010

Positive interim results from NxStage Medical's FREEDOM study in RLS

NxStage Medical, Inc., a leading manufacturer of innovative dialysis products, today announced the latest interim results from its ongoing FREEDOM study, which show the significant improvement of overall sleep quality and marked improvement in Restless Legs Syndrome (RLS) experienced by patients after four months of daily home hemodialysis therapy with the NxStage System One™.

8 Mar 2010

Moderating treatment response in depression: Role of personality factors

A study published in the current issue of Psychotherapy and Psychosomatics addresses the role of personality factors in moderating treatment response in depression.

8 Mar 2010

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

Argos Therapeutics today announced the presentation of positive data from a Phase 2 trial that evaluated the safety, clinical response and immune response of AGS-003 treatment in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). The data were discussed March 7 in a poster presentation at the ASCO Genitourinary Cancers Symposium.

8 Mar 2010

VIVUS granted three additional patents for Qnexa

VIVUS, Inc. today announced the issuance of three additional patents by the U.S. Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents are the second, third, and fourth patents to be granted in a series of patent applications VIVUS has filed that are directed to the Qnexa product and methods of using Qnexa in various therapeutic applications.

8 Mar 2010

New nutrition product to address effects of Glycation

After an extensive on going research program, Mineral BioSciences LLC a division of Global Organics Group is proud to announce the introduction of TOTALA® Nutrients, an ingredient that promises to have a profound effect on the nutrition industry.

8 Mar 2010

Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals

Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.

8 Mar 2010

NICE rejects azacitidine for treatment of MDS in patients ineligible for stem cell transplants

A drug for treating a group of conditions that affect the bone marrow is unlikely to be made available on the NHS in England and Wales after the body which provides independent advice on treatments said that it is unlikely to be cost-effective.

8 Mar 2010

Evaluating asymptomatic diabetics for CHD: Speckle Tracking by Echo ultrasound substudy sponsored

Cardiovascular death is the most common cause of mortality among Type 2 diabetics and claims the lives of millions each year, with many diabetics experiencing their first “symptom” as a heart attack or sudden death. Understanding that diabetics are at high risk for Coronary Heart Disease (CHD) and that many with the disease are asymptomatic, Toshiba America Medical Systems, Inc., has sponsored Speckle Tracking by Echo, a faCTor64 substudy using Toshiba’s Wall Motion Tracking ultrasound technology.

8 Mar 2010

DaVita's presentations at ADC: New developments in the field of CKD, Vascular Access and Home Modalities

DaVita Inc., a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), in conjunction with DaVita Clinical Research®, today announced that company representatives will present 20 presentations at the 30th Annual Dialysis Conference scheduled for March 6 – 9 in Seattle.

8 Mar 2010

MS Awareness Week: Time for nation to go orange and move it to end MS

MS Awareness Week March 8-14 is the time for the nation to go orange and move it to end multiple sclerosis, a disease where someone is newly diagnosed every hour of every day. Supported by a Congressional resolution, this year MS Awareness Week and the state of MS research aptly coincide. Move it to create a world free of MS!

8 Mar 2010

World Heart Federation to open WCC Scientific Sessions 2010 in Beijing, China

In 100 days the World Heart Federation, with the support of the Chinese Society of Cardiology and the Chinese Medical Association, will open the World Congress of Cardiology (WCC) Scientific Sessions 2010 in Beijing, China.

8 Mar 2010

NSF's Sleep in America poll finds differences in sleep habits and attitudes among ethnic groups

The 2010 Sleep in America poll released today by the National Sleep Foundation reveals significant differences in the sleep habits and attitudes of Asians, Blacks/African-Americans, Hispanics and Whites. It is the first poll to examine sleep among these four ethnic groups.

8 Mar 2010

Medical Condition News

Study finds sizeable position for Actemra in rheumatoid arthritis treatment paradigm

New program specifically tailored to teens could help them manage and avoid asthma

RDS launches international outreach program on cognitive impairment in Down syndrome patients

ISTA Pharmaceuticals' sNDA for once-daily XiDay: FDA assigns PDUFA action date

ImmunoGen receives FDA orphan drug designation for IMGN901 compound in treatment of MCC

FDA approves Taro Pharmaceutical Industries' Fluorouracil Topical Cream ANDA

BioSpecifics Technologies' XIAFLEX now available to Dupuytren's contracture patients in the U.S.

Rcadia Medical Imaging receives CE Mark for COR Analyzer System

Positive interim results from NxStage Medical's FREEDOM study in RLS

Moderating treatment response in depression: Role of personality factors

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

VIVUS granted three additional patents for Qnexa

New nutrition product to address effects of Glycation

Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals

NICE rejects azacitidine for treatment of MDS in patients ineligible for stem cell transplants

Evaluating asymptomatic diabetics for CHD: Speckle Tracking by Echo ultrasound substudy sponsored

DaVita's presentations at ADC: New developments in the field of CKD, Vascular Access and Home Modalities

MS Awareness Week: Time for nation to go orange and move it to end MS

World Heart Federation to open WCC Scientific Sessions 2010 in Beijing, China

NSF's Sleep in America poll finds differences in sleep habits and attitudes among ethnic groups

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News